Nevertheless, the results of the present study showed an increasing trend in pre- and post-bronchodilator FEV 1 in both groups after medication initiation, similar to the results of the five discussed RCTs ( 5 ).
← all excerpts
Efficacy and safety of a proposed omalizumab biosimilar compared to the reference product in the management of uncontrolled moderate-to-severe allergic asthma: a multicenter, phase III, randomized, double-blind, equivalency clinical trial.
1
—
—